Thus, in the present study, we have assessed the efficacy of the selective MasR agonist, AVE0991, to provide neuroprotection under ischemia-like conditions in vitro, and following post-ischemic administration in an in vivo model of stroke. The gene discussed is MAS1L; the disease is ischemia.